Company intelligence / Profile preview

Dragon Overseas Capital

Hong Kong, Hong Kong

Ownership: Private
Development stage: Other

Overview

OT-101 has completed several phase 2 trials (brain cancer, pancreatic cancer, COVID-19); top-line safety and efficacy data reported as positive for COVID-19 in November 2021.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Antisense oligonucleotideSmall molecule
Industry: Investors

Partnerships

Oncotelic TherapeuticsGolden Mountain Partners, LLC

Beyond the preview

Go deeper on Dragon Overseas Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dragon Overseas Capital.

Explore the full profile